Status:
RECRUITING
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Conditions:
Hepatocellular Carcinoma
Solid Tumor, Adult
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
To study the safety and clinical effect of injection of drug-eluting microspheres with multiple chemodrug and/or protein drugs into advanced solid tumors.
Detailed Description
Drug-eluting microspheres such as DC-beads will be loaded with IL2, PD1/PDL1/CTLA4 antibody, or /and VEGF/VEGFR antibody with or without doxorubicin/idarubicin for various time and injected into tumor...
Eligibility Criteria
Inclusion
- Solid advanced malignant tumors
- Age between18 and 99 years
- Life expectancy is greater than three months
Exclusion
- Benign tumor
- Life expectancy is less than three months
- Serious medical comorbidity
- Others
Key Trial Info
Start Date :
November 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2035
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04770207
Start Date
November 1 2020
End Date
November 1 2035
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510260